The "Deemed To Be a License" Provision of the BPCI Act; Questions and Answers; Guidance for Industry
Details
The document's own metadata, straight from the source system.
- Title
- The "Deemed To Be a License" Provision of the BPCI Act; Questions and Answers; Guidance for Industry
- Posted
- Mar 5, 2020
- Comment period
- Mar 5, 2020 – ?
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Campaigns
Organized form-letter drives, separated from organic one-off comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- 4 comments from the past week
4 comments match your current view and arrived in the last week. Read this week's comments with stance, commenter type, and AI summaries on the paid plan.
- Jul 29, 2026Comment from Sylvester, RobinOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 29, 2026Comment from Karapetyan, MominaOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 29, 2026Comment from Burbank, BrigetteOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Murgo, PeggyOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Forsdick, JessicaOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Hunter, SarahOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Kellogg Lillien, Elizabeth AnneOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Peterson, NannetteOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Webb Danya-DeeOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment → - Jul 28, 2026Comment from Affolder JudithOpposeIndividual
A patient expresses concern over the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change will create barriers to access, increase costs, and eliminate options for patients who rely on DTE from compounding pharmacies.
Read comment →